Global Antiviral Therapeutics Market Size Study, By Drug, By Therapy, By Distribution Channel, and Regional Forecasts 2022-2032

Description

The Global Antiviral Therapeutics Market is valued approximately at USD 75.53 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.28% over the forecast period 2024-2032. Antiviral therapeutics are specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. These drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics.

Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth. The escalating demand for antiviral drugs is significantly attributed to the global surge in the prevalence of viral diseases, necessitating the development of effective therapeutic solutions. Stringent regulatory frameworks emphasizing the safety and efficacy of antiviral medications also contribute to the robust market growth. Despite the challenges posed by the high cost of drug development and potential side effects, advancements in pharmaceutical research and development continue to propel the antiviral therapeutics market forward. Moreover, the integration of novel technologies in drug formulation and delivery is anticipated to enhance the market's growth prospects. However, side effects associated with antiviral drugs and the high cost of development of medication hamper the growth of antiviral therapeutics.

The key regions considered for the global antiviral therapeutics market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is expected to hold a significant share of the market due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Europe is also anticipated to contribute significantly to market growth, driven by stringent regulatory standards and substantial healthcare expenditure. The Asia Pacific region is projected to witness the highest growth rate, fueled by increasing investments in healthcare infrastructure, rising awareness about viral diseases, and a large patient population.

Major market players included in this report are:

Abbott Laboratories
AbbVie Inc.
Alkem Laboratories Limited
AstraZeneca PLC
Atea Pharmaceuticals, Inc.
Aurobindo Pharma Limited
Bristol-Myers Squibb Company
Cipla Ltd.
Cocrystal Pharma, Inc.
Daiichi Sankyo Company, Ltd.
Dr. Reddy's Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
GlaxoSmithKline PLC

The detailed segments and sub-segment of the market are explained below:

By Drug:

Hepatitis Antiviral Drug
Herpes Antiviral Drug
HIV Antiviral Drug
Influenza Antiviral Drug

By Therapy:

DNA Polymerase Inhibitors
Non-nucleosides
Purine Nucleoside Analogues
Pyrimidine Nucleoside Analogues
Neuraminidase Inhibitors
Protease Inhibitors
Reverse Transcriptase Inhibitors

By Distribution:

Hospital Pharmacy
Independent Pharmacy & Drug Store
Online Pharmacy
Common content for 'Report Description'

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Antiviral Therapeutics Market Executive Summary

1.1. Global Antiviral Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Drug
- 1.3.2. By Therapy
- 1.3.3. By Distribution
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Antiviral Therapeutics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Antiviral Therapeutics Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Viral Diseases
- 3.1.2. Increasing Pharmaceutical Research & Development
- 3.1.3. Growing Healthcare Expenditure
3.2. Market Challenges
- 3.2.1. Side Effects of Antiviral Drugs
- 3.2.2. High Cost of Drug Development
3.3. Market Opportunities
- 3.3.1. Advancements in Drug Development Technologies
- 3.3.2. Growing Demand for Personalized Medicine
- 3.3.3. Expansion in Emerging Markets

Chapter 4. Global Antiviral Therapeutics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Antiviral Therapeutics Market Size & Forecasts by Drug 2022-2032

5.1. Segment Dashboard
5.2. Global Antiviral Therapeutics Market: Drug Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Hepatitis Antiviral Drug
- 5.2.2. Herpes Antiviral Drug
- 5.2.3. HIV Antiviral Drug
- 5.2.4. Influenza Antiviral Drug

Chapter 6. Global Antiviral Therapeutics Market Size & Forecasts by Therapy 2022-2032

6.1. Segment Dashboard
6.2. Global Antiviral Therapeutics Market: Therapy Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. DNA Polymerase Inhibitors
- 6.2.2. Non-nucleosides
- 6.2.3. Purine Nucleoside Analogues
- 6.2.4. Pyrimidine Nucleoside Analogues
- 6.2.5. Neuraminidase Inhibitors
- 6.2.6. Protease Inhibitors
- 6.2.7. Reverse Transcriptase Inhibitors

Chapter 7. Global Antiviral Therapeutics Market Size & Forecasts by Distribution 2022-2032

7.1. Segment Dashboard
7.2. Global Antiviral Therapeutics Market: Distribution Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital Pharmacy
- 7.2.2. Independent Pharmacy & Drug Store
- 7.2.3. Online Pharmacy

Chapter 8. Global Antiviral Therapeutics Market Size & Forecasts by Region 2022-2032

8.1. North America Antiviral Therapeutics Market
- 8.1.1. U.S. Antiviral Therapeutics Market
  - 8.1.1.1. Drug breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Therapy breakdown size & forecasts, 2022-2032
  - 8.1.1.3. Distribution breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Antiviral Therapeutics Market
8.2. Europe Antiviral Therapeutics Market
- 8.2.1. UK Antiviral Therapeutics Market
- 8.2.2. Germany Antiviral Therapeutics Market
- 8.2.3. France Antiviral Therapeutics Market
- 8.2.4. Spain Antiviral Therapeutics Market
- 8.2.5. Italy Antiviral Therapeutics Market
- 8.2.6. Rest of Europe Antiviral Therapeutics Market
8.3. Asia-Pacific Antiviral Therapeutics Market
- 8.3.1. China Antiviral Therapeutics Market
- 8.3.2. India Antiviral Therapeutics Market
- 8.3.3. Japan Antiviral Therapeutics Market
- 8.3.4. Australia Antiviral Therapeutics Market
- 8.3.5. South Korea Antiviral Therapeutics Market
- 8.3.6. Rest of Asia Pacific Antiviral Therapeutics Market
8.4. Latin America Antiviral Therapeutics Market
- 8.4.1. Brazil Antiviral Therapeutics Market
- 8.4.2. Mexico Antiviral Therapeutics Market
- 8.4.3. Rest of Latin America Antiviral Therapeutics Market
8.5. Middle East & Africa Antiviral Therapeutics Market
- 8.5.1. Saudi Arabia Antiviral Therapeutics Market
- 8.5.2. South Africa Antiviral Therapeutics Market
- 8.5.3. Rest of Middle East & Africa Antiviral Therapeutics Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Abbott Laboratories
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. AbbVie Inc.
- 9.3.3. Alkem Laboratories Limited
- 9.3.4. AstraZeneca PLC
- 9.3.5. Atea Pharmaceuticals, Inc.
- 9.3.6. Aurobindo Pharma Limited
- 9.3.7. Bristol-Myers Squibb Company
- 9.3.8. Cipla Ltd.
- 9.3.9. Cocrystal Pharma, Inc.
- 9.3.10. Daiichi Sankyo Company, Ltd.
- 9.3.11. Dr. Reddy's Laboratories Ltd.
- 9.3.12. Eli Lilly and Company
- 9.3.13. F. Hoffmann-La Roche Ltd
- 9.3.14. Gilead Sciences, Inc.
- 9.3.15. GlaxoSmithKline PLC

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes